title: FDG PET/CT in monitoring response to treatment in gynecological malignancies.
abstract: OBJECTIVE
  To evaluate the role of fluorodeoxyglucose (FDG) PET/CT as cancer response testing in gynecological malignancies.
  
  
  RESULTS
  The application of FDG PET/CT in patients with endometrial and ovarian cancer to evaluate treatment response was found to have no clinical benefits.Patients with cervical cancer seem to benefit from the use of PET/CT in estimation of treatment response. The influence of different treatments on FDG uptake, timing, frequency of examination, and survival advantage are evaluated and discussed.
  
  
  CONCLUSIONS
  Growing evidence supports an important role for functional imaging FDG PET/CT as a monitoring tool in patients with uterine-cervix carcinoma. Further studies are needed to establish the clinical benefits of this modality in this population.
authors.affiliation: Department of Obstetrics and Gynecology, Gynecologic Oncology Unit, Rambam Healthcare Campus, Haifa, Israel. a_amit@rambam.health.gov.il
authors.forename: Amnon
authors.initials: A
authors.lastname: Amit
authors.forename: Orit
authors.initials: O
authors.lastname: Person
authors.forename: Zohar
authors.initials: Z
authors.lastname: Keidar
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D019788:Fluorodeoxyglucose F18; D005833:Genital Neoplasms, Female / Q000000981:diagnostic imaging* / Q000188:drug therapy; D006801:Humans; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18